Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Weill Cornell NY Presbyterian Hospital
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Weill Cornell NY Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Mt. Sinai Medical Center
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Hillman Cancer Center
mi
from
Pittsburgh, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Institute for Translational Oncology Research
mi
from
Greenville, SC
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Tyler Cancer Center
mi
from
Tyler, TX
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
VA Oncology Associates
mi
from
Norfolk, VA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
VA Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Virginia Mason Medical Center
mi
from
Seattle, WA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated:  9/26/2012
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated: 9/26/2012
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Status: Enrolling
Updated:  9/27/2012
Rush Unversity Medical Center
mi
from
Chicago, IL
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Status: Enrolling
Updated: 9/27/2012
Rush Unversity Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated:  9/28/2012
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated: 9/28/2012
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated:  9/28/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated: 9/28/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated:  9/28/2012
Park Meadows Cosmetic Surgery
mi
from
Lone Tree, CO
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated: 9/28/2012
Park Meadows Cosmetic Surgery
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated:  9/28/2012
Mercy Medical Center
mi
from
Baltimore, MD
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated: 9/28/2012
Mercy Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated:  9/28/2012
Sanford Clinic Plastic and Reconstructive Surgery
mi
from
Sioux Falls, SD
Evaluation of the Cook Biodesign Plastic Surgery Matrix
A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix
Status: Enrolling
Updated: 9/28/2012
Sanford Clinic Plastic and Reconstructive Surgery
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors
Status: Enrolling
Updated:  9/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors
Status: Enrolling
Updated: 9/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
St. Joseph's Hospital & Medical Center St Jospeh's
mi
from
Phoenix, AZ
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
St. Joseph's Hospital & Medical Center St Jospeh's
mi
from
Phoenix, AZ
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
City of Hope National Medical Center City of Hope national Med Ctr
mi
from
Duarte, CA
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
City of Hope National Medical Center City of Hope national Med Ctr
mi
from
Duarte, CA
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
H. Lee Moffitt Cancer Center/University of South Florida Moffitt 3
mi
from
Tampa, FL
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
H. Lee Moffitt Cancer Center/University of South Florida Moffitt 3
mi
from
Tampa, FL
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Holy Cross Hospital Holly Cross
mi
from
Silver Spring, MD
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Holy Cross Hospital Holly Cross
mi
from
Silver Spring, MD
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Henry Ford Hospital Henry Ford
mi
from
Detroit, MI
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Henry Ford Hospital Henry Ford
mi
from
Detroit, MI
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Washington University School Of Medicine-Siteman Cancer Ctr Wash U
mi
from
St. Louis, MO
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Washington University School Of Medicine-Siteman Cancer Ctr Wash U
mi
from
St. Louis, MO
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Morristown Memorial Hospital MMH
mi
from
Morristown, NJ
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Morristown Memorial Hospital MMH
mi
from
Morristown, NJ
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Carolinas HealthCare Systems Blumenthal Cancer Center
mi
from
Charlotte, NC
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Carolinas HealthCare Systems Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Cancer Centers of North Carolina Cancer Centers of NC-Raleigh
mi
from
Raleigh, NC
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Cancer Centers of North Carolina Cancer Centers of NC-Raleigh
mi
from
Raleigh, NC
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
University of Oklahoma Health Sciences Center OU Health
mi
from
Oklahoma City, OK
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
University of Oklahoma Health Sciences Center OU Health
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Oregon Health & Science University (OHSU)
mi
from
Portland, OR
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Oregon Health & Science University (OHSU)
mi
from
Portland, OR
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Northwest Cancer Specialists Vancouver Location
mi
from
Portland, OR
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Northwest Cancer Specialists Vancouver Location
mi
from
Portland, OR
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Geisinger Health System GHS
mi
from
Danville, PA
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Geisinger Health System GHS
mi
from
Danville, PA
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Sarah Cannon Research Institute SCRI (2)
mi
from
Nashville, TN
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Sarah Cannon Research Institute SCRI (2)
mi
from
Nashville, TN
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Texas Oncology, P.A. Austin
mi
from
Bedford, TX
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Texas Oncology, P.A. Austin
mi
from
Bedford, TX
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Texas Oncology, P.A. Tex Onc (3)
mi
from
Bedford, TX
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Texas Oncology, P.A. Tex Onc (3)
mi
from
Bedford, TX
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
University of Texas Southwestern Medical Center Obstetrics and Gynecology
mi
from
Dallas, TX
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
University of Texas Southwestern Medical Center Obstetrics and Gynecology
mi
from
Dallas, TX
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
US Oncology Central Monitoring
mi
from
Dallas, TX
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
US Oncology Central Monitoring
mi
from
Dallas, TX
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
South Texas Oncology and Hematology, PA South Tex Onc
mi
from
San Antonio, TX
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
South Texas Oncology and Hematology, PA South Tex Onc
mi
from
San Antonio, TX
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Pacific Gynecology Specialists PGS
mi
from
Seattle, WA
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Pacific Gynecology Specialists PGS
mi
from
Seattle, WA
Click here to add this to my saved trials
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated:  9/30/2012
Cancer Care Northwest CC Northwest- Spokane South(3)
mi
from
Spokane, WA
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Status: Enrolling
Updated: 9/30/2012
Cancer Care Northwest CC Northwest- Spokane South(3)
mi
from
Spokane, WA
Click here to add this to my saved trials
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Status: Enrolling
Updated:  10/1/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Status: Enrolling
Updated: 10/1/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/1/2012
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC
mi
from
Tampa, FL
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/1/2012
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC
mi
from
Tampa, FL
Click here to add this to my saved trials
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/1/2012
Wayne State University/Karmanos Cancer Institute Wayne/Karmanos
mi
from
Detroit, MI
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/1/2012
Wayne State University/Karmanos Cancer Institute Wayne/Karmanos
mi
from
Detroit, MI
Click here to add this to my saved trials
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/1/2012
South Texas Accelerated Research Therapeutics START
mi
from
San Antonio, TX
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/1/2012
South Texas Accelerated Research Therapeutics START
mi
from
San Antonio, TX
Click here to add this to my saved trials
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/1/2012
University of Utah / Huntsman Cancer Institute Huntsman UT
mi
from
Salt Lake City, UT
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/1/2012
University of Utah / Huntsman Cancer Institute Huntsman UT
mi
from
Salt Lake City, UT
Click here to add this to my saved trials